Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

Technology appraisal guidance
Reference number: TA478
Published: 04 October 2017

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 238 KB)

Published:

04 October 2017

Final appraisal determination

Final appraisal determination
Final appraisal determination document (PDF 484 KB)

Published:

24 August 2017
Committee papers (PDF 5.13 MB)

Published:

24 August 2017
Public committee slides (PDF 627 KB)

Published:

24 August 2017

Draft guidance: 1

Draft guidance: 1
Appraisal consultation document (PDF 206 KB)

Published:

14 June 2017
Committee papers (PDF 9.49 MB)

Published:

14 June 2017
Public committee slides (PDF 983 KB)

Published:

14 June 2017
Public committee slides (PDF 729 KB)

Published:

14 June 2017

Invitation to participate

Final scope (PDF 100 KB)

Published:

02 December 2016
Final matrix (PDF 173 KB)

Published:

02 December 2016
NICE's response to comments on the draft scope and provisional matrix (PDF 109 KB)

Published:

02 December 2016
Equality Impact Assessment (Guidance development) (PDF 172 KB)

Published:

02 December 2016